Bioventus reports Q4 non-GAAP EPS 15c, consensus 8c

Reports Q4 revenue $153.6M, consensus $145.16M. “Our Bioventus (BVS) team delivered strong results in the fourth quarter to conclude a very successful and transformational year for our company,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “Looking forward, we believe we are well positioned to build on this positive momentum, driving above-market revenue growth with a multitude of diverse growth drivers, while enhancing profitability and accelerating cash flow to create significant shareholder value.”